2 Oral - Tailored axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer patients is safe: 3-year follow-up of the MARI protocol.

Authors :: Van Loevezijn, A.
van der Noordaa, M.E.M.
van Duijnhoven, F.
Groen, E.J.
Stokkel, M.P.M.
Loo, C.E.
Elkhuizen, P.
Russell, N.S.
Vrancken-Peeters, M.J.
Source :: European Journal of Cancer. 2020 Supplement 1, Vol. 138, pS3-S4. 2p.
Publication Year :: 2020

Subjects :: *BREAST tumor treatment
*COMBINED modality therapy
*CONFERENCES & conventions
*PATIENT safety
*INDIVIDUALIZED medicine

Full Text Access

Tools